ABSTRACT Background: Genetic factors that predispose individuals to nonalcoholic fatty liver disease (NAFLD) and associated diabetes and cardiovascular disease are unclear. The transcription factor sterol regulatory element-binding protein-1c (SREBP-1c) modulates lipogenesis and insulin sensitivity and was experimentally connected to NAFLD. Objective: We assessed the impact of a common SREBF-1c polymorphism on the incidence and severity of NAFLD and on associated glucose and lipoprotein dysmetabolism. Design: We followed up 212 randomly selected, nonobese, nondiabetic, insulin-sensitive participants in a population-based study without NAFLD or metabolic syndrome at baseline who were characterized for the common SREBF-1c gene rs11868035 A/G polymorphism, dietary habits, physical activity, adipokine profile, C-reactive protein (CRP), and circulating markers of endothelial dysfunction. A comparable cohort of NAFLD patients underwent a liver biopsy, an oral-glucose-tolerance test with minimal model analysis of glucose homeostasis variables, and an oral-fat-tolerance test with measurement of plasma lipoproteins, adipokines, and cytokeratin-18 fragments. Results: SREBF-1c predicted the 7-y incidence of NAFLD (OR: 1.71; 95% CI: 1.15, 2.53) and diabetes and the 7-y elevation in CRP and endothelial dysfunction markers. In biopsy-proven NAFLD patients, the SREBF-1c A allele conferred increased risk of severe steatosis and nonalcoholic steatohepatitis; more-severe hepatic, muscle, and adipose tissue insulin resistance; and pancreatic b cell dysfunction. SREBF-1c A allele carriers also had an impaired oral fat tolerance with a postprandial accumulation of large triglyceriderich lipoproteins and oxidized LDLs, lower HDL cholesterol and adiponectin concentrations, and cytokeratin-18 fragment elevation. Conclusion: SREBF-1c polymorphism is associated with increased risk of developing NAFLD with more severe liver histology and derangement in glucose and lipoprotein metabolism, which contribute to the presentation and natural history of NAFLD.
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) 4 , which is the most-common chronic liver disease, encompasses a histologic spectrum that ranges from simple steatosis to steatosis plus necroinflammation [nonalcoholic steatohepatitis (NASH)], which can be differentiated only by a liver biopsy. Although simple steatosis has a benign hepatologic course, NASH can progress to end-stage liver disease and is projected to be the leading cause of liver transplantation by 2020 (1); furthermore, both histologic subtypes confer increased risk of type 2 diabetes (T2D) and cardiovascular disease (CVD) through mechanisms that potentially involve adipokine and lipoprotein dysregulation (1) . The scant prospective data on factors predisposing to NAFLD and associated cardiometabolic disorders have linked baseline metabolic syndrome, insulin resistance and hyperinsulinemia, and weight gain to incident ultrasonographic NAFLD (2, 3); however, not every insulin-resistant or obese subject develops NAFLD and NASH, which suggests that additional genetic or environmental factors promote liver disease in insulin-resistant subjects (4) .
A genetic predisposition to NAFLD and NASH is indisputably present, and different polymorphisms in genes that regulate lipid metabolism, including apolipoprotein E (apoE), and patatin-like phospholipase domain-containing 3 (PNPLA3), have been crosssectionally connected to the presence and severity of NAFLD (5, 6) . However, it is unclear whether these cross-sectional associations between different single-nucleotide polymorphisms (SNPs) and NAFLD were direct or mediated by other factors, including insulin resistance or obesity, and whether these SNPs also affect NAFLD-associated cardiometabolic risk, which represents a significant health-related burden for these patients (1) .
Dysregulated hepatic de novo lipogenesis has been implicated not only in liver fat accumulation but also in altered glucose and lipid metabolism observed in experimental NAFLD (7) . The sterol regulatory element-binding factor (SREBF)-1c gene codes for the key nuclear transcription factor sterol regulatory element binding protein (SREBP)-1c, which has been shown to regulate de novo lipogenesis and hepatic insulin sensitivity. and triglyceriderich lipoprotein metabolism experimentally; consistently, SREBP-1c overexpression induced insulin resistance, diabetes, NAFLD, and accelerated atherosclerosis in mice (8) (9) (10) . SNPs in the SREBF-1c gene have been connected to metabolic disorders in humans. Specifically, the SNP rs11868035 A/G, located in the intron region of the SREBF-1c gene modulated risk of type 2 diabetes, insulin resistance, obesity, and hypercholesterolemia in different ethnicities, with the A allele being at risk of these conditions (11) (12) (13) (14) (15) . Therefore, we hypothesized this SNP in the SREBF-1c gene may confer genetic susceptibility to NAFLD and affect NAFLD-associated cardiometabolic risk through the modulation of glucose and lipoprotein metabolism.
We aimed to 1) prospectively assess the impact of the SREBF1c SNP on risk of developing NAFLD in initially insulinsensitive, nonobese, nondiabetic subjects and 2) elucidate potential mechanisms that connect the SREBF-1c SNP to liver injury and glucose and lipid homeostasis in biopsy-proven NAFLD.
SUBJECTS AND METHODS

Subjects
On the basis of available cross-sectional data that showed an SREBF-1c rs11868035 A/G minor allele frequency of 30% and a prevalence of NAFLD of 25% (2, 3) , with the assumption of an effect size $2 (OR for NAFLD) and allowance for a 10% dropout rate, $189 subjects were needed to detect a significant (P , 0.05) difference in NAFLD incidence between SREBF-1c genotypes with a power of 80%.
In 1611 white subjects aged 45-64 y who participated in a metabolic survey in the province of Asti (North-Western Italy) in 2004-2005 (previously described) (16) , 227 randomly selected subjects gave informed consent to be included in the study. At baseline, all subjects were in good general health, with normal findings on a medical history, physical examination, and chemical screening battery. Subjects with diabetes, obesity, metabolic syndrome, insulin resistance, CVD, significant alcohol consumption (see Definitions), liver-enzyme elevation [including serum alanine aminotransferase (ALT) .30 IU/L in men and .20 IU/L in women, according to proposed cutoffs that enhance the sensitivity for steatosis detection and have a .95% negative predictive value for the presence of steatosis] (17-19) or known liver disease (see Definitions and online supplemental material under "Supplemental data" in the online issue) were excluded from the study, which was approved by the local ethics committee and conformed to the Helsinki Declaration.
Baseline data collected during the period 2004-2005 included the following measurements: weight, height, and waist circumference, blood pressure after a uniform protocol; a dietary and physical activity record (see Dietary and physical activity record); and routine biochemistry. Frozen serum samples collected from all participants at entry were stored at 2808C for genetic and biochemical analyses. From June 2011 to November 2012, participants in the baseline survey were submitted to a follow-up evaluation. All anthropometric, dietary, and physical activity records and biochemical analyses were repeated at the end of follow-up.
Definitions
The presence of NAFLD was suggested by persistently (.6 mo) elevated liver enzymes (including a serum ALT concentration $30 IU/L in men and $20 IU/L in women) and confirmed by an abdomen ultrasonography made by using a 3.5-MHz probe by 2 experienced radiologists blinded to data of participants. An ultrasonographic diagnosis of steatosis was based on recently proposed standardized criteria, which substantially improved the diagnostic accuracy of ultrasonography (20) .
Exclusion criteria were as follows: a history of alcohol consumption .20 g/d in men and .10 g/d in women (assessed by a detailed inquiry of patients and relatives and a validated questionnaire filled in daily for 1 wk by patients) or positive serum markers of viral hepatitis B-C; see online supplementary material under "Supplemental data" in the online issue for a description of other competing causes of hepatic steatosis that were excluded. Diabetes was defined by a fasting plasma glucose concentration $126 mg/dL or 2-h plasma glucose concentration $200 mg/dL during an oral-glucose-tolerance test (OGTT) or by drug treatment of elevated plasma glucose; obesity was defined by BMI (in kg/m 2 ) $30. Insulin resistance was defined by a homeostasis model assessment of insulin resistance index $2, which is a cutoff that is closely correlated with clamp measures in Northern Italian subjects and OGTTderived indexes of insulin sensitivity in our subjects with NAFLD (21) . Metabolic syndrome was defined according to the joint International Diabetes Federation, National Heart, Lung, and Blood Institute, American Heart Association, International Atherosclerosis Society, and International Association for the Study of Obesity statement (22) (see Table 1 footnote 1 for details).
Dietary and physical activity record
Subjects were instructed to fill in a 7-d validated and reproducible diet record during an individual training session with a nutritionist; a list of foods was designed, and for each item, different portion sizes were specified according to the European Prospective Investigation into Cancer study (23, 24) . The recorded period included a complete week. The diet record was analyzed by using the WinFood database (PRO version; Medimatica) according to the table of food consumption of the Italian National Institute of Nutrition (25) and Food Composition Database for Epidemiologic Study in Italy (26) .
Patients were interviewed about smoking habits and completed the Minnesota-Leisure-Time-Physical-Activity questionnaire (27) . The physical activity level was calculated as the product of duration and frequency of each activity (in h/wk), weighed by an estimate of the metabolic equivalent of the activity, and summed for activities performed.
Proinflammatory markers, adipokines, and markers of endothelial dysfunction
See online supplementary material under "Supplemental data" in the online issue for a description of the assessment of serum C-reactive protein (CRP), adiponectin, and resistin. Circulating soluble adhesion molecules E-selectin and intercellular adhesion molecule-1 were measured as validated markers of endothelial dysfunction, subclinical atherosclerosis, and early CVD (28, 29) . See online supplementary material under "Supplemental data" in the online issue for details of laboratory analyses.
Genetic analyses
The functional SNP rs11868035 A/G in the intron region of the SREBF-1c gene was assessed by using the real-time allele discrimination methods with a TaqMan Allelic Discrimination Assay (Applied Biosystems). We also genotyped our population for common SNPs in 3 genes that have been linked to both lipid metabolism and risk of NAFLD as follows: rs738409 C/G in the PNPLA3 gene, sterol regulatory binding factor (SREBF-2) gene polymorphism, and apoE genotype (5, 6, 30) (see online supplementary material under "Supplemental data" in the online issue for details).
Impact of SREBPF-1 SNPs on liver histology, glucose homeostasis, lipoprotein, and adipokine profile in biopsyproven NAFLD
To investigate the impact of SREBPF-1c SNP on liver disease, glucose, and lipoprotein metabolism, a cohort of biopsy-proven NAFLD patients was selected who were comparable for age, sex, and BMI to the overall group of new-onset NAFLD. Biopsyproven NAFLD patients and matched control subjects underwent a standard OGTT and an oral-fat-tolerance test. To limit the confounding effect of age, sex, and obesity on the severity of NAFLD and on variables of glucose and lipoprotein metabolism, NAFLD patients and control subjects were matched for age, sex, BMI, and SREBPF-1c SNP (see online supplementary Table 2 under "Supplemental data" in the online issue).
Because of the low prevalence of at-risk A-allele homozygotes and overlapping clinical characteristics with heterozygous AG carriers, SREBF-1c AA carriers were combined with the AG genotype for a group comparisons. In biopsy-proven NAFLD patients, each pathologic feature of liver biopsy was read and scored by a single pathologist (E David) blinded to the patient clinical-biochemical characteristics and scored according to the NASH Clinical Research Network criteria, and NASH was defined according to Brunt criteria (see online supplementary material under "Supplemental data" in the online issue). Subjects with newly diagnosed diabetes were excluded to avoid the confounding effect of T2D on glucose homeostasis, adipokine profile, and lipoprotein metabolism.
Glucose homeostasis
A minimal model analysis of plasma glucose, insulin, and C-peptide during the OGTT yielded the following variables of glucose homeostasis (see online supplementary material under "Supplemental data" in the online issue): whole-body insulin sensitivity index, hepatic and muscle insulin resistance index, 2 indexes of b cell function (the insulinogenic index, and the C-peptide-genic index), and 2 integrated indexes of b cell function (ie, the disposition index and adaptation index, which relate b cell insulin secretion to insulin resistance and were previously validated against frequently sampled intravenous-glucose-tolerance test minimal model variables of glucose homeostasis in NAFLD and nondiabetic subjects) (31, 32) .
Adipose tissue insulin resistance index was calculated as fasting free fatty acids (FFAs) multiplied by fasting insulin (33) .
Oral-fat-tolerance test
Postprandial lipemia is an emerging CVD risk factor, and we hypothesized that SREBF-1c would modify the lipotoxicity of an oral fat load (4, 34) . Consistently, NAFLD patients and control subjects underwent a 10-h oral-fat-tolerance test (3) (see online supplementary material under "Supplemental data" in the online issue for details). Blood samples were drawn every 2 h for 10 h, and the following variables were measured at each time-point: 1) Plasma total cholesterol, triglyceride, FFA, HDL cholesterol, and apolipoprotein A1 were measured by using automated enzymatic methods. HDL2 cholesterol and HDL3 cholesterol was determined (see online supplementary material under "Supplemental data" in the online issue for details).
2) Triglyceride-rich lipoproteins were isolated through preparative ultracentrifugation and subfractionated, and their triglyceride, cholesterol, apolipoprotein B100, and apolipoprotein B48 contents were determined (see online supplementary material under "Supplemental data" in the online issue for details).
3) Circulating oxidized LDLs (oxLDLs), adipokines (resistin and adiponectin), and cytokeratin-18 fragments, which are a validated marker of hepatocyte apoptosis (1), were also assessed (see online supplementary material under "Supplemental data" in the online issue).
Statistical analysis
Participants with and without follow-up visits were compared with determine the appropriateness of an analysis on the basis of participants with complete data only. Hardy-Weinberg equilibrium was assessed by using the chi-square test. Comparisons of genotype frequencies between NAFLD developers and non-NAFLD developers were performed by using 2 3 2 contingency tables with chi-square analysis.
Subjects with and without NAFLD at the end of the follow-up were compared for baseline values and changes during follow-up. Normality was evaluated by using the Shapiro-Wilk test, and nonnormal values were log-transformed for regression analysis. The Fisher's or chi-square test were used to compare categorical variables, as appropriate.
In the follow-up cohort, differences across groups were analyzed by ANOVA and Bonferroni correction, when variables were normally distributed; otherwise the Kruskal-Wallis test, followed by the post hoc Dunn test, was used to compare nonparametric variables. For the analysis of the cohort of 84 matched subjects (42 biopsy-proven NAFLD subjects and 42 age-, sex-, and BMImatched control subjects, paired t tests (parametric), pairedsample sign test and Wilcoxon's signed-rank tests were used.
To adjust for multiple comparison testing, the BenjaminiHochberg false-discovery rate correction was applied to raw P values. Significance was set at an adjusted P value threshold of 0.05 (35) .
The analysis of lifestyle, anthropometric and metabolic variables, and genetic polymorphisms was made by using Spearman's correlation test. Genetic polymorphisms were modeled as an additive effect [ie, quantitative predictor variables that reflected the number of risk alleles (0, 1, or 2)].
SREBF-1C AND NAFLD
On the basis of results of a univariate analysis, a logistic regression model was used to identify independent predictors of incident NAFLD and NASH, incident T2D, and markers of subclinical atherosclerosis at the end of follow-up. Variables were selected from variables that differed between NAFLD and non-NAFLD developers at baseline and during follow-up (D values).
The AUC and incremental AUC (IAUC) of variables measured during the oral fat test and OGTT in patients with biopsy-proven NAFLD and control subjects were computed by using the trapezoid method. Univariate regression analysis was used to identify independent predictors of glucose and lipid homeostasis variables and different histologic features in biopsy-proven NAFLD. To evaluate predictors of the severity of liver histology and variables related to glucose and lipid metabolism in matched groups, a conditional regression analysis was used, and matched ORs for different outcome variables were calculated.
Quartiles of continuous variables were considered in all analyses. Data were expressed as means 6 SEMs (STATISTICA software, 5.1; Statsoft Italia).
RESULTS
Subject characteristics at baseline and end of follow-up in the entire cohort
After a mean follow-up period of 7.2 6 0.3 y, data on 212 participants were available for follow-up examinations ( Table  1) . The 15 subjects (7.1%) lost at follow-up did not significantly differ in baseline anthropometric, lifestyle, clinical, or biochemical features from the other participants included in the analysis. At the end of follow-up, 51 subjects (24%) developed ultrasonographic NAFLD.
At the end of follow-up, NAFLD patients had significantly higher BMI, CRP, fasting insulin, and HOMA-IR and lower plasma adiponectin concentrations than did non-NAFLD developers. Thirty percent of NAFLD patients compared with 16% of non-NAFLD developers had elevated fasting plasma glucose (P = 0.027), and 13% of NAFLD patients compared with 2% of non-NAFLD developers had T2D (P = 0.002)( Table 1) .
The SREBF-1c A allele frequency was 52% in NAFLD developers compared with 32% in non-NAFLD developers (P = 0.013) ( Table 2) . SREBF-1c GG carriers were 62% in non-NAFLD developers compared with 39% in NAFLD developers (P = 0.007), heterozygous AG carriers were 28% in non-NAFLD developers compared with 33% in NAFLD developers (P = 0.576) and homozygous AA carriers were 10% in non-NAFLD developers compared with 27% in NAFLD developers (P = 0.004) ( Table 1) .
PNPLA3 G allele carriers were also more frequent in NAFLD developers than in non-NAFLD developers, which was consistent with the existing literature (5 ) (Tables 1-2 ). Genotype frequencies were in Hardy-Weinberg equilibrium, and allele frequencies were consistent with published reports in the white population (5, 6, (11) (12) (13) (14) .
At baseline, there was no significant difference in any other genetic, anthropometric, lifestyle, clinical, or biochemical features between NAFLD developers and non-NAFLD developers or in SREBF-1c genotypes (Table 1; see online supplementary  Table 1 under "Supplemental data" in the online issue). There was also no significant difference in physical activity or dietary habits between NAFLD and non-NAFLD developers throughout the study (Table 1; see online supplementary Table 2 under "Supplemental data" in the online issue).
Impact of SREBF-1c SNP on incident NAFLD, T2D, and CVD risk markers at the end of follow-up in the entire cohort SREBF-1c and PNPLA3 SNPs with the A and the G allele, respectively, that confer increased risk predicted incident NAFLD together with BMI changes; SREBF-1c SNP also predicted incident T2D together with BMI changes and the highest CRP, E-selectin, and intercellular adhesion molecule-1 quartiles at the end of follow-up ( Table 3) .
Impact of SREBF-1c SNP on BMI changes
The SREBF-1c A allele (OR: 1.50; 95% CI: 1.04, 2.21; P = 0.028) and age (OR: 1.41; 95% CI: 1.11, 2.13; P = 0.032) predicted the BMI increase during the follow-up.
Impact of SREBF-1c SNP on liver histology in biopsyproven NAFLD
A liver biopsy, which was performed in 42 NAFLD patients, showed NASH in 21subjects (50%) (see online supplementary Table 3 under "Supplemental data" in the online issue).
Steatosis was mild in 32% of NAFLD patients, moderate in 39% of NAFLD patients, and severe in 29% of NAFLD patients. Lobular inflammation was absent in 37% of patients, grade 1 in 20% of patients, grade 2 in 23% of patients, and grade 3 in 20% of patients. Hepatocyte ballooning was absent in 42% of patients, grade 1 in 35% of patients, and grade 2 in 23% of patients. The mean NAFLD activity score in the overall NAFLD cohort was 3.9 6 0.5. Fibrosis was stage 0 in 54% of patients, stage 1 in 15% of patients, stage 2 in 18% of patients, and stage 3 in 13%% of patients; cirrhotic changes were absent.
In NAFLD patients, SREBF-1c GA/AA carriers had moresevere histologic steatosis, necroinflammation, higher NAFLD activity score and fibrosis score, and a higher prevalence of NASH than did GG genotype carriers (see online supplementary Table 3 under "Supplemental data" in the online issue). In the conditional logistic regression analysis, the SREBF-1c SNP was independently associated with the presence of severe steatosis (OR: 1.80; 95% CI: 1.24, 2.40; P = 0.008) and NASH (OR: 1.70; 95% CI: 1.19, 2.20; P = 0.009) ( Table 4) .
Impact of SREBF-1c SNP on glucose homeostasis in biopsy-proven NAFLD As a group, NAFLD patients had more-severe insulin resistance and pancreatic b cell dysfunction than did the 42 matched healthy control subjects ( Table 5) . In both NAFLD patients and control subjects, SREBF-1c GA/AA carriers displayed more severe hepatic, muscle, and adipose tissue insulin resistance and pancreatic b cell dysfunction (as assessed by using the insulinogenic index, disposition index, C-peptidegenic index, and adaptation index) than did GG carriers (Table 5 ). In a logistic regression analysis, the SREBF-1c SNP was independently associated with hepatic and adipose tissue insulin resistance and pancreatic b cell dysfunction (Table 4) . 
SREBF-1C AND NAFLD
Impact of SREBF-1c SNP on oral fat tolerance in biopsyproven NAFLD
Postprandial lipemia
As a group, NAFLD patients had a higher postprandial lipemia than that of healthy control subjects (Table 5 ). In both NAFLD and control subjects, SREBF-1c GA/AA carriers showed higher IAUC of triglycerides and FFAs than did GG genotype carriers; the increased postprandial lipemia was accounted for by a higher IAUC of large intestinal and hepatic VLDL1 lipoproteins (Table  5 ; see online supplementary Figure 1 under "Supplemental data" in the online issue). In a logistic regression analysis, SREBF-1c was independently associated with postprandial IAUCs of triglyceride and intestinal and hepatic VLDL1 (Table 4) .
Oxidized LDL and HDL responses
As a group, NAFLD patients had higher postprandial IAUC of LDL conjugated dienes, chosen as markers of oxLDLs, and lower IAUC of HDL cholesterol than did healthy control subjects (Table 5) . SREBF-1c GA/AA carriers also displayed a significant increase in IAUC of oxLDL and a fall in HDL cholesterol and apolipoprotein A-I concentrations. The fall in HDL cholesterol was accounted for by a reduction in the larger HDL2 subfraction. In a logistic regression analysis, hepatic IAUC of VLDL1 independently predicted postprandial HDL cholesterol and apolipoprotein A-I responses (Table 4 ; see online supplementary Figure 2 under "Supplemental data" in the online issue).
Adiponectin and cytokeratin-18 responses
As a group, NAFLD patients had lower postprandial adiponectin concentrations than those healthy control subjects (Table 5) . In both NAFLD patients and control subjects, postprandial adiponectin concentrations were lower, whereas circulating cytokeratin-18 fragments were higher in SREBF-1c GA/AA carriers than GG genotype carriers (Table 5 ; see supplementary Figure 2 under "Supplemental data" in the online issue). In a logistic regression analysis, SREBF-1 SNP was independently associated with the postprandial adiponectin response (Table 4) . 1 P values refer to the comparison between groups at baseline and at the end of follow-up and to the comparison in changes during follow-up, respectively. Subjects with and without NAFLD at the end of the follow-up were compared for baseline values and changes during follow-up. Normality was evaluated by using the Shapiro-Wilk test. Fisher's test or the chi-square test was used to compare categorical variables as appropriate. Differences across groups were analyzed by using ANOVA followed by Bonferroni correction when variables were normally distributed; otherwise, the Kruskal-Wallis test followed by the post hoc Dunn test were used to compare nonparametric variables. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BP, blood pressure; CRP, C-reactive protein; FPG, fasting plasma glucose; GGT, g-glutamyltransferase; ICAM-1, intercellular adhesion molecule-1; MET, metabolic equivalent task; Met Sy, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; PNPLA3, patatin-like phospholipase domain-containing 3; SREBF, sterol regulatory element-binding factor; T2D, type 2 diabetes.
2 Mean 6 SEM (all such values). 3 According to the joint statement of American Heart Association, International Diabetes Federation, and National Heart, Lung, and Blood Institute; requires the presence of $3 of the following criteria: abdominal obesity (waist circumference $102 cm in men and $88 cm in women); high triglycerides ($150 mg/dL) or receiving a drug treatment of elevated triglycerides; low HDL cholesterol [,40 mg/dL in men and ,50 mg/dL in women) or receiving a drug treatment of reduced HDL cholesterol; hypertension (systolic BP $130 mm Hg or diastolic BP $85 mm Hg or receiving drug treatment; and high FPG ($100 mg/dL) or receiving a drug treatment of elevated glucose.
DISCUSSION
Main findings of this study were as follows: 1) In nonobese, nondiabetic, insulin-sensitive subjects without metabolic syndrome at baseline, SREBF-1c SNPs predicted the 7-y incidence of NAFLD and diabetes and elevation in CRP and endothelial dysfunction markers at the end of follow-up.
2) In biopsy-proven NAFLD patients, the SREBF-1c SNP was correlated with the severity of steatosis and necroinflammation and the presence of NASH.
3) In biopsy-proven NAFLD patients and matched control subjects, the SREBF-1c SNP was associated with impaired glucose homeostasis and lipoprotein and adiponectin responses to fat ingestion.
SREBF-1c codes for the nuclear transcription factor SREBP1c, which a well-known regulator of hepatic lipogenesis and insulin sensitivity. Animal and cross-sectional human studies previously connected increased hepatic SREBP-1c expression to hepatic steatosis and insulin resistance, which are effects that are at least partially mediated by the enhanced synthesis of lipotoxic saturated fatty acids and increased hepatic gluconeogenesis (9, 36, 37) . However, thus far, it was unclear if enhanced SREBP-1c expression could be a primary defect that promotes NAFLD development or simply mediates the hepatic effects of other obesity-associated factors, including hyperinsulinemia and high dietary carbohydrate and saturated fat intakes, which are all potent SREBP-1c inducers (9) . Therefore, we studied a common SNP in SREBF-1c in nonobese insulin-sensitive subjects without metabolic syndrome or diabetes at baseline and showed that it predisposed individuals to NAFLD and diabetes development at the end of follow-up. Some peculiarities differentiated this study from previous studies: first, to our knowledge, our study was the first prospective genetic study on NAFLD. The study design may have relevant implications when evaluating a multifactorial disease such as NAFLD; although SNPs are primary in nature, their association with NAFLD may be substantially affected by the interaction with other lifestyle and metabolic factors, including aging, diet, physical activity, whole-body and abdominal fat accumulation, adipose tissue dysfunction, and insulin resistance, which have not been taken into account by most studies on genetic predisposition to NAFLD (38) . This lack may at least in part explain why most genetic associations failed to be replicated in independent studies. Available prospective studies showed an association between baseline insulin resistance, overweight, or metabolic syndrome with incident NAFLD but did not elucidate factors that predisposed subjects to fat accumulation and the development of insulin resistance. For the effective primary prevention of NAFLD-related comorbidities, we need to discover which subjects, of those who may become overweight and insulin resistant, are genetically predisposed to liver-related and cardiometabolic complications to direct them to aggressive preventive measures and tight monitoring. Our data suggest SREBF-1c genotyping may be functional to this aim. Several mechanisms may underlie the association of the SREBF-1c rs11868035 A/G SNP with the presence of NASH. SFEBF-1c may promote hepatic synthesis of lipotoxic FFA, which may directly promote hepatocyte apoptosis and necroinflammation (36, 37) . Postprandial lipolysis of accumulating triglyceride-rich lipoproteins my also provide another source of lipotoxic FFAs for hepatocytes, as suggested by the correlation of the postprandial cytokeratin-18-fragment elevation with the FFA response (37, 38) (Table 4) .
Adipose tissue dysfunction (32, 39) , as defined by adipose tissue insulin resistance and an impaired adiponectin response to fat ingestion, aggravating hepatocyte exposure to lipotoxic FFA may have also contributed to SREBF-1c-mediated liver injury and deranged cardiometabolic homeostasis in our patients. Consistently, selective adipocyte SREBP-1c overexpression induced adipocyte insulin resistance and a proinflammatory pattern of adipokine secretion that led to diabetes, hypertriglyceridemia, and liver injury, which occurred even in the absence of obesity development and indicated that the relation between SREBP-1c and adipose tissue function is direct and not mediated by fatdepot enlargement (9, 40) .
The association of the SREBF-1c SNP with incident diabetes in our population may be explained by the extensive modulation of tissue insulin resistance and pancreatic b cell function (Tables  4-5 ). Consistently, in cellular and animal models, enhanced pancreatic SREBP-1c expression extensively downregulated TABLE 4 Conditional logistic regression analysis of significant predictors of variables related to liver histology, glucose homeostasis, and oral fat tolerance in biopsy-proven NAFLD subjects and matched control subjects (n = 84) 1 Forty-two patients with biopsy-proven NAFLD and 42 matched control subjects (total: 84 subjects) were included in the conditional regression analysis, and matched ORs (95% CIs) were calculated for target outcomes. For liver histology, outcome variables were severe (involving $66% hepatocytes) steatosis, presence of NASH as defined by Brunt criteria (see supplementary material under "Supplemental data" in the online issue), and advanced (stages 3-4) fibrosis. For continuous variables of glucose and lipid homeostasis, quartiles were considered, and the upper quartile of different variables was considered as the target condition. For the SREBF-1c polymorphism, the OR expresses risk of having the target condition of SREBF-1c GA/AA compared with GG carriers. The steatosis score is the score for steatosis severity according to NASH Clinical Research Network criteria, ranging from 1 (mild; involving 5-33% hepatocytes) to 3 (severe; involving .66% hepatocytes); the NAFLD-activity score is the sum of scores for steatosis, hepatocellular ballooning, and lobular inflammation (range: 1-8); and the fibrosis score is the stage of fibrosis, ranging from 0 (absent) to 3 (advanced). Cirrhotic (stage 4) changes were absent in our patients. FFA, free fatty acid; IAUC, incremental AUC; IR, insulin resistance; IS, insulin sensitivity; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; OGIS, oral glucose insulin sensitivity index; PNPLA3, patatin-like phospholipase domain-containing 3; SREBF-1c, sterol regulatory element-binding factor-1c. SREBF-1C AND NAFLD multiple functional pathways required for insulin secretion, including a decreased ATP production, repressed insulin receptor substrate-2 signaling, and an impaired post-ATP membrane voltage-dependent activation (41, 42) . In these models, b cell function was restored by PUFA administration, which implicated a therapeutic potential of PUFAs for correcting impaired SREBP-1c-mediated insulin secretion (42) . In our subjects, the SREBF-1c SNP also modulated also changes in endothelial adhesion molecules, which are validated markers of endothelial dysfunction, subclinical atherosclerosis, and CVD risk (28, 29) , suggesting SREBF-1c also affects cardiovascular risk, at least in part through the modulation of lipoprotein metabolism; consistent with our findings, in mice, hepatic SREBP-1c affected the susceptibility to atherosclerosis by controlling the size of nascent VLDL particles (8, 10) , and SREBP-1c activation promote the secretion of large VLDL particles, which accumulate in the plasma postprandially because of competition with chilomicrons and exchange lipids with HDL and LDL particles that become smaller and denser, yielding a highly atherogenic lipoprotein profile (8, 10) .
Consistent with available data (12), the SREBF-1c SNP also predicted BMI changes during follow-up, together with age. In the absence of detectable differences in nutrient intake and physical activity, we speculate that, in at-risk genotypes, SREBP1c-mediated de novo lipogenesis interacts with age-related decline in basal metabolic rate to promote adipose tissue expansion and weight gain (43).
Our study had strengths and limitations. Strengths were the careful selection, thorough characterization of participants, and histologic characterization of NAFLD, whereas limitations were the small number of patients, and the ultrasonographic definition of steatosis, which may have missed some cases of milder fat infiltration. However, recent standardized criteria significantly improved the ultrasonographic diagnostic accuracy for detecting even minor degrees of steatosis (20) , and the combination of ultrasonography with recently proposed and validated lower ALT cutoffs should have enhanced the ability to rule out cases of even mild steatosis in non-NAFLD subjects. Finally, our study was performed on a specific population (ie, a relatively older population with the exclusion of obese and diabetes patients at baseline) and may, thus, not be applicable to the entire population.
In conclusion, our data suggest SREBP-1c modulates the genetic susceptibility to the whole spectrum of health-related risk in NAFLD by extensively affecting multiple metabolic steps at hepatic and extrahepatic sites. If our findings are confirmed in large population-based cohorts from different ethnicities, genotyping NAFLD patients for the SREBF-1c SNP may help select patients at greater liver-related and cardiometabolic risk for early experimental treatments and tight monitoring. Future research should clarify the impact of this SNP on SREBF-1c function and elucidate molecular mechanisms that link SREBF-1c to liver injury, adipokine secretion and action, and lipoprotein metabolism. Therapeutically, it should be assessed whether SREBP-1c pathway modulation may prevent multisystemic consequences of All values are means 6 SEMs. n = 84. IGI = Dinsulin30#/Dglucose30# ratio during the oral-glucose-tolerance test; disposition index = IGI 3 OGIS; CGI = DC-peptide30#/Dglucose30# ratio during the oral-glucose-tolerance test; adaptation index = CGI 3 OGIS. The disposition index and adaptation index were computed by multiplying IGI or CGI, respectively, by OGIS. Hepatic extraction is the percentage of secreted insulin extracted by the liver. Normality was evaluated by using the Shapiro-Wilk test. Fisher's test or the chi-square test was used to compare categorical variables as appropriate. AUC and IAUC of variables measured during the oral fat test and oral-glucose-tolerance test in patients with biopsy-proven NAFLD and control subjects were computed by using the trapezoid method. Differences across groups were analyzed by using ANOVA followed by Bonferroni correction when variables were normally distributed; otherwise, the Kruskal-Wallis test followed by the post hoc Dunn test were used to compare nonparametric variables. P-genotype us the P value for the main effect of the SREBF-1c G/A genotype; P-interaction is the P value for the interaction between the SREBF-1c G/A genotype 3 status (control or NAFLD). To adjust for multiple-comparison testing, the Benjamini-Hochberg false-discovery rate correction was applied to raw P values; significance was set at an adjusted P-value threshold of 0.05. CD, conjugated dienes; CGI, C-peptide-genic index; FFA, free fatty acid; IAUC, incremental AUC; IGI, insulinogenic index; IR, insulin resistance; IS, insulin sensitivity; NAFLD, nonalcoholic fatty liver disease; OGIS, oral-glucose insulin-sensitivity index; SREBF-1c, sterol regulatory element-binding factor-1c. lipotoxicity more effectively than can currently available strategies (44) .
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